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Introduction {#sec1}
============

Chronic suppurative otitis media (CSOM) is chronic inflammatory condition of the middle ear cleft with permanent perforation, ear discharge and hearing loss. Clinicians dispute the duration of otorrhea for more than three months.[@bib1], [@bib2] There are two types of CSOM and these are safe or unsafe depending on the presence of cholesteatoma[@bib3]: Safe CSOM is CSOM without cholesteatoma and can be subdivided into *active* or *inactive* depending on whether or not infection is present. Unsafe CSOM is often associated with cholesteatoma which may lead to fatal complications.

The most common bacteria for CSOM are *Pseudomonas aeruginosa*, *Klebsiella* sp., *Proteus* sp., and *Staphylococcus aureus*.[@bib4] Whereas, the bacteria commonly isolated from patients with acute otitis media (AOM) are *Moraxella catarrhalis* and *Streptococcus pneumonia*, *Haemophilus influenzae*.[@bib5] Additionally, the *P. aeruginosa* had been seen as a notorious pathogen in the hospital too.[@bib6], [@bib7] Certainly, the ability to form biofilm by these organisms contributes to their frequency in CSOM.[@bib8] It is often found in immune compromised patient as compared to the normal patients.[@bib9] Mostly, with several clonal variants of the bacteria were resistant to the penicillin group of antibiotics, after which different antibiotics were introduced for the control.[@bib10] The most horrible situation is that Methicillin resistant *Staphylococcus aureus* (MRSA) strains have emerged with subsequent resistance to most commonly used antibiotics of groups, macrolides, aminoglycosides, fluoroquinolones, chloramphenicol and tetracycline and many more such as, to cephalosporin, cefepime and other betalactams, ampicillin-sulbactam, amoxicillin-clavulanic acid, ticarcillin-clavulanic acid, piperacillin-tazobactam and the carbapenem, imipenem. So the isolated MRSA are MDR too.[@bib11] In a study extended spectrum beta lactamases (ESBL) and ampicillin were detected in 11 (18.3%) and 12 (20.0%) Gram negative bacteria, respectively. Whereas the MBL producer was not detected.[@bib12]

This work describes the surveillance of bacterial flora from ear infections of patients attending the Outpatients Department (OPD) of Otorhinolaryngology department of the hospital, in a year. Antibiotic sensitivity pattern of isolated bacterial were determined to assess the variety of CSOM that would help in empirical therapy with the antimicrobial stewardship program of the teaching hospital at the eastern India. Also, the incident of ESBL and MBL strains from the CSOM were documented.

Materials and methods {#sec2}
=====================

Selection of CSOM patients {#sec2.1}
--------------------------

CSOM is a long-standing suppurative middle ear infection with permanent perforation, otorrhea and hearing loss with duration of more than three months. CSOM patients were diagnosed clinically by the consultant otolaryngologist. On the basis of clinical presentations and otoscopic examinations, patients were selected for this study. The patients of acute infections of the middle ear cleft of less than three months and traumatic perforations of the tympanic membrane were excluded from this study. The pus is collected from the ear canal in CSOM patients with the help of the sterile ear swab (Himedia mumbai PW003) by consultant otolaryngologist with all aseptic measures.

Study population {#sec2.2}
----------------

A total of 500 ear swabs from clinically diagnosed CSOM cases were collected, during July 2016 to June 2017 with sterile cotton swab sticks. Pus swabs were cultured on blood and MacConkey agar plates that were incubated at 37 °C overnight for pathogenic bacteria, which were identified according to the standard method used for bacteria ([Fig. 1](#fig1){ref-type="fig"}A--F).[@bib13] Antibiotic susceptibility tests of isolated bacteria were done according to Clinical Laboratory Standard Institute guidelines ([Fig. 2](#fig2){ref-type="fig"}A--C), as described.[@bib14] Standard antimicrobial disks (HiMedia, Mumbai) used for isolated bacteria were amikacin 30, gentamicin 30, ciprofloxacin, amoxyclav 30, aztreonam 30, piperacillin 100, piperacillin/tazobactam 100/10, cefepime 30, cefoperazone 75, cefoperazone/sulbactam 75/30, ceftazidime 10, ceftriaxone 10, imipenem 10, gatifloxacin 30, Oxacilin and Vancomicin. The standard MTCC strains and all the clinical isolated bacteria were subjected to antibiotic sensitivity tests with antibiotics, by the Kirby--Bauer\'s method (disk diffusion) detailed previously.[@bib11]Fig. 1Macroscopic photograph of isolated bacteria on specific medium from human chronic suppurative otitis media A: *Stphylococcous aureus*; B: *Pseudomonas aeruginosa*; C: *Acenetobacter baumanii*; D: *Citrobacter freundii*; E: *Enterobacter* sp.; F: *Proteus* sp.Fig. 1Fig. 2Antibiotic sensitivity pattern of isolated bacteria from human chronic suppurative otitis media on MHA (Mueller Hinton Agar) A: *Psueudomonas aeruginosa*; B: *Acenetobacter baumanii*; C: *Citrobacter fruindii*.Fig. 2

Detection of MBL strain {#sec2.3}
-----------------------

The metallo β-lactamases (MBL) production was detected by the imipenem -- EDTA-DDST. The organisms were considered to be MBL producers, if the increase in the inhibition zone of the β-lactam + EDTA disc was ≥5 mm ([Fig. 3](#fig3){ref-type="fig"}A--C).[@bib15] The MBL production in this isolate, for the synergy test imipenem-EDTA disk was used developed, as followed. Earlier reports have recommended that the imipenem-EDTA disk synergy test is a reliable method for initial screening of MBL production in clinical isolates.[@bib16]Fig. 3Detection of Metallobetalactamases (MBL) and extended spectrum beta lactamases (ESBL) with disc diffusion methods A: MBL strain of *Pseudomonas aeruginosa*; B: MBL strain of *Klebsiela pneumaneae*; C: ESBL strain of *Citrobacter freundii*; D: ESBL strain of *Acenetobacter baumanii*.Fig. 3

Detection of ESBL strains {#sec2.4}
-------------------------

The double disc synergy test (DDST) was used to detect the ESBL producing activity of selected bacterial strains on a lawn culture on a MH agar plate. The augmentin 30 μg disc (20 μg amoxicillin and 10 μg clavulanic acid) in the middle was flanked by a disc of ceftazidime 30 μg and a disc of cefotaxime 30 μg (both third generation cephalosporin), at 30 mm apart on a lawn culture. The set up was done in triplicates and plates were incubated at 37 °C for overnight for observation of inhibition zones. With the augmentin disc inhibition the action of the ESBL enzyme give an inhibition zone, which was formed from a peripheral disc towards the middle, due to the synergistic action of the augmentin and the corresponding cephalosporin disc ([Fig. 3](#fig3){ref-type="fig"}D). In general, if the organism is resistant to both cephalosporins, because of the production of the ESBL enzyme, the action of augmentin deactivated the enzyme with a consequent reactivation of a cephalosporin resulting in the extension of the inhibition zone.[@bib17]

Results {#sec3}
=======

Growth of bacteria from ear swabs of CSOM patients {#sec3.1}
--------------------------------------------------

A total of 500 ear swabs were subjected to culture on specific culture media for bacterial growth. In this study the prevalence of bacteria among CSOM patients was 82.6%. It was observed that varieties of colonies were grown on the specific cultured medium. In certain plate single type of colony and in other cases two, three or more than 3 types of colonies were grown. The percentage of frequency of the colony was documented ([Table 1](#tbl1){ref-type="table"}). The single colony frequency was found more as compare to other types of colonies from the ear swab. Three or more colonies were treated as contaminated samples. With specific culture media different type of colonies were grown and it was identified with conventional method by both macroscopically and biochemically ([Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). All the grown positive bacteria were processed with catalase and coagulase and *Staphylococcus aureus* were identified basing upon the results of catalase and coagulase. Similarly all the gram negative bacterial were processed with different biochemical tests and basing up on their results the bacteria were identified ([Table 3](#tbl3){ref-type="table"}). For the species identification the carbohydrate fermentation tests were carried out and results were documented ([Table 4](#tbl4){ref-type="table"}).Table 1Number of varieties of colony observed macroscopically on the cultured plate.Table 1No. of different ColonyFrequencyNumber of bacteriaPercentage of bacteria isolated (%)No growth87017.4Single colony21621643.2Two colony8416816.8Three or more colony29Treated as contaminatedTotal50038476.8Table 2dentification of bacteria with culture morphology.Table 2BacteriumMTCC no.Agar mediaColony morphology*Staphylococcus aureus*7443Nutrient agarGolden yellow, opaque, circular colonies white butyrous consistencyMannitol salt agarYellow colonies,*Acinetobacter baumannii*1425Nutrient agar (NA)Colourless smooth, opaque, raised and pinpoint colonies.MacConkey agarColourless smooth, opaque, raised, NLF colonies*Enterobacter* aerogenes2990Blood agarSmall, round and pin -point colony.MacConkey agarLF and mucoid colonies*Citrobacter freundii*1658MacConkey agarLate LF colonies light pink after 48 h*Klebsiella* sp.4031MacConkey agarLF, pink, mucoid colonies.CLED agarYellow and mucoid colonies*Proteus* sp.1771Blood agarSwarming coloniesCLEDtranslucent blue colonies*Pseudomonas aeruginosa*1688Nutrient agar,Large, irregular opaque colonies, with bluish green pigment.[^1]Table 3Summary of results of biochemical tests of isolated Gram-negative bacteria.Table 3BacteriaCatalaseOxidaseIndoleMRVPCitrateUreaseTSINitrateMotility*A. baumannii*+------++VND--M*Citrobacter* sp.+----+--+--K/A + H~2~S+M*Enterobacter* sp+------++VA/A+M*K. oxytoca*+--+--+++A/AG+NM*K. pneumoniae*+------+++A/AG+NM*P. vulgaris*+----+--V+K/A H~2~S+M*P. mirabilis*+--++--V+K/A H~2~S+M*P. aeruginosa*++------++ND+M[^2]Table 4Summary of results of carbohydrate fermentation tests of isolated Gram-negative bacteria.Table 4BacteriaGlucoseLactoseSucroseMaltoseMannitol*A. baumannii*----------*Citrobacter* sp.A + GLLF+++*Enterobacter* sp.A + GA+++*P. vulgaris*G------+*P. mirabilis*G------+*K. oxytoca*A + GA+--+*K. pneumoniae*A + GA+--+*P. aeruginosa*A--++V[^3]

Antibiotic sensitivity test of isolated bacteria from CSOM patients {#sec3.2}
-------------------------------------------------------------------

From the antibiotic tests, it was revealed that ceftazidime (CAZ) was highest resistant (78%) to *A. baumannii* and Amoxyclav is the highest sensitive (86%) to *A. baumannii*. Similarly the antibiotic resistance percentage for other bacteria was documented ([Table 5](#tbl5){ref-type="table"}). But in CSOM patients were prescribed the antibiotic amoxyclav and ciprofloxacin mainly. The ciprofloxacin is resistant to 20% to *A. baumannii*, 12% to *C. freundii*, 51% to *E. aerogenes*, *32% to K. oxytoca*, 62% *to K. pneumonia*, 81% *to P. vulgaris*, 31% *to P. mirabilis*, 28% *to P. aeruginosa and* 43% *to S. aureus*. Similarly, Amoxyclav is resistant to 14% to *A. baumannii*, 31% to *C. freundii*, 32% to *E. aerogenes*,*16% to K. oxytoca*, 21% *to K. pneumonia*, 25% *to P. vulgaris*, 23% *to P. mirabilis*,17% *to P. aeruginosa and* 38% to *S. aureus* ([Table 5](#tbl5){ref-type="table"}).Table 5Percentage of antibiotic resistance with corresponding bacteria (μg/disc).Table 5BacteriaAKGENCIPAMCATPIPITCPMCPZCFSCAZCTRIPMGATOXV*A. baumannii*2330201471302171623478722120----*C. freundii*78123163403969521582743122----*E. aerogenes*7856513260783461562474684216----*K. oxytoca*2436321674822554622182743819----*K. pneumoniae*6383622161872857712189825671----*P. vulgaris*6948812558913464521691925869----*P. mirabilis*4954312346692178611478793778----*P. aeruginosa*6859281751672383733173743931----*S.aureus*754643388759--6853482743--395436[^4]

Incidence of ESBL and MBL strains from CSOM patients {#sec3.3}
----------------------------------------------------

All the strains were screened for ESBL and MBL and it was revealed that 74.22% ESBL and 9.90% MBL strains were found. Among the ESBL strains 89 *S. aureus* and 79 *P. aeruginosa* strains were found. Similarly, 2.08% *S. aureus* and 4.43% *P. aeruginosa* MBL strains were found during this study period ([Table 6](#tbl6){ref-type="table"}).Table 6Number of isolated ESBL and MBL strains from Gram negative (GN) bacteria.Table 6BacteriaNumber of isolated strains%ESBL strain% with respective bacteria% with total bacteriaMBL strain% with respective bacteria% with total bacteria*A. baumannii*5313.803464.158.85611.321.56*C. freundii*266.771142.312.8613.850.26*E. aerogenes*328.331856.254.69000.00*K. oxytoca*246.252083.335.21000.00*K. pneumoniae*184.699502.3415.560.26*P. vulgaris*235.992191.35.4728.700.52*P. mirabilis*102.604401.04330.000.78*P. aeruginosa*11229.178979.4623.1887.142.08*S. aureus*8622.407991.8620.571719.774.43*Total*384100.0028574.2274.22389.909.90[^5]

Discussion {#sec4}
==========

In this study the prevalence of bacteria among CSOM patients was 82.6%. This was in tandem with reports from other parts of 91.7%,[@bib18] 89.4%,[@bib19] 89.5%,[@bib20] 100%[@bib21] and Nigeria, 81.9%.[@bib22] Gram-negative bacteria, 59.6% were the dominant isolates of the discharging ears compared to gram-positive bacteria. Similar reports were seen from Gonder 56.4%,[@bib20] Dessie 74.2%,[@bib18] Addis Ababa 60.5%[@bib23] and Nigeria 75%[@bib24] though the proportion varies.

The CSOM is a major health problem both in children and adults world-wide, but more so in developing countries. It can cause chronic hearing loss which has a negative impact on the development of speech, language and social interaction as well as school and workplace performance and is responsible for significant morbidity and mortality due to complications. According to a report by WHO, India belongs to the highest (\>4%) CSOM prevalent countries.[@bib4] Topical antibiotics are the mainstay of therapy while systemic antibiotics are given in acute exacerbations and in complications due to CSOM.[@bib25] The poor living conditions, less access to medical care, poor medical treatment, recurrent upper respiratory tract infections and the nasal diseases have been recognized as risk factors for CSOM.[@bib25] Atticoantral disease is the most commonly involved with the posterior superior part of the middle ear cleft and it is characterized by the formation of a retraction pocket with cholesteatoma; eventually it is considered to be a dangerous form of the disease because of the development of several intracranial and extra-cranial complications.[@bib26] Moreover, staphylococci are a part of the normal flora, but those remain invasive causing a variety of body infections. *S. aureus* is the most notorious nosocomial pathogen and in community too.[@bib27] Although the clinical relevance of Coagulase negative *Staphylococcus Sp.* (CONS) is still controversial; patients at risk of CONS infections include neonates, those with intravascular catheters, prosthetic devices and surgical wounds in the immune-compromised individuals. The remarkable ability of *S. aureus* and CONS to acquire antibiotic resistance limits therapeutic options, attended with high rates of morbidity and mortality, including costs of hospitalization.[@bib28], [@bib29] Particularly, several clonal variants of *S. aureus* and MRSA were reported resistant to the penicillin group of antibiotics, methicillin/oxacillin. Moreover, in a German study, it was reported that a majority of MRSA strains were from wound infections (56.9%), with pneumonia cases being the second most common (21.0%), followed by BSI (15.1%).[@bib30]

In our study, from 500 samples 384 bacteria were isolated. In other studies, Nazir et al[@bib31] and Sanjana et al[@bib32] have reported less number of bacteria as compare to our study results. Gram negative bacteria predominance (60.6%) matches other studies in India.[@bib33] *S. aureus* was the predominant bacteria followed by *P. aeruginosa* which are in opposite with other studies.[@bib4], [@bib34] Whereas similar results reported in other studies i.e. *S. aureus* as predominant isolate followed by *P. aeruginosa*.[@bib35], [@bib36], [@bib37] In this study higher resistance demonstrated in Gram positive bacteria 54% *S. aureus* exhibiting methicillin resistance. On the other hand resistance among Gram negative bacteria was much lower with 9.90% MBL producer detected but high rate of 74.22% ESBL strains documented.

Conclusion {#sec5}
==========

CSOM is a common clinical entity where topical and systemic antibiotic are the main treatment. However the emergence of antibiotic resistant strains is leading to increasing treatment failure. MDR strains of *P. aeruginosa* and MRSA were most prevalent in ear discharges of patients with CSOM. Continuous and periodic evaluation of microbiological profile and antimicrobial sensitivity pattern of bacterial is essential for optimum management of CSOM patients.
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[^1]: MTCC: Microbial type culture collection; Na: not available; EMB: Eosin methylene blue agar; XLD: Xylose lysine deoxycholate; CLED: cystine lactose electrolyte deficient medium; LF, lactose fermenting; NLF: Non-lactose fermenting.

[^2]: +: positive; --: negative; V: variable; MR: methyl red; VP: Voges-Proskauer; TSI: triple sugar iron; A: acid; K: alkali; G: gas; H~2~S: H~2~S production; M: motile; NM: non-motile; ND: not done.

[^3]: A: acid; A + G: acid + gas; V: variable; LLF: late lactose fermentation; LSF: late sucrose fermentation; +: positive; --: negative.

[^4]: Ak: amikacin 30; GEN: gentamicin 30; CIP: ciprofloxacin; AMC: amoxyclav 30; AT: aztreonam 30; PI: piperacillin 100; PIT: piperacillin/tazobactam 100/10; CPM: cefepime 30; CPZ: cefoperazone 75; CFS: cefoperazone/sulbactam 75/30; CAZ: ceftazidime 10; CTR: ceftriaxone 10; IPM: imipenem 10 (Carbap., carbapenem); GAT: gatifloxacin 30; OX: Oxacilin; V:Vancomicin.

[^5]: ESBL: Extended spectrum beta lactamse; MBL: mettalo beta lactamase.
